"Novo Nordisk said on Thursday that a once-daily pill version of Wegovy achieved significant weight loss in a clinical trial, with close to one in three participants losing 20% or more weight. Side-effects were similar to the injectable version. It is the first oral GLP-1 drug submitted to the US regulator, the Food and Drug Administration, and the company expects a decision on whether the FDA will approve it for use by the end of the year."
"The Danish company is going head to head with Eli Lilly's daily weight loss pill, called orforglipron. On Tuesday, the US drugmaker said that one in five people lost 20% or more weight over 72 weeks, in a trial of 3,127 adults. Patients lost 12.4% of their body weight on average at the highest dose. It developed orforglipron with a compound it acquired from Japan's Chugai Pharmaceutical in 2018."
Novo Nordisk’s market value rose by more than £6.5bn after a once-daily oral version of Wegovy produced significant weight loss in a clinical trial. Close to one in three participants lost 20% or more weight and side-effects were similar to the injectable version. The pill is the first oral GLP-1 submitted to the FDA, with an approval decision expected by year-end and US production already under way. Eli Lilly’s rival orforglipron showed one in five people lost 20% or more weight over 72 weeks, with analysts forecasting strong peak sales and noting differences in scalability and dosing convenience.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]